Arca
Skip to content
Tools
Tools

FCGR2B: Low affinity immunoglobulin gamma Fc region receptor II-b

Receptor for the Fc region of complexed or aggregated immunoglobulins gamma.

  • Drugs that act on it: 1
  • Approved: 0
  • In phases 1 to 3: 1
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on FCGR2B, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 1

Approved0

    Phase 31

    • Obexelimab

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        ObexelimabPhase 3Zenas BioPharmaAntibodyInhibitorLow affinity immunoglobulin gamma Fc region receptor II-b inhibitor4

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 4 in all, from ClinicalTrials.gov.
        A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)ObexelimabPhase 2Active, not recruitingZenas BioPharma (USA), LLCAug 21, 2024
        A Study of Obexelimab in Patients With Systemic Lupus ErythematosusObexelimabPhase 2Active, not recruitingZenas BioPharma (USA), LLCAug 19, 2024
        A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)ObexelimabPhase 3Active, not recruitingZenas BioPharma (USA), LLCMar 27, 2023
        A Phase 3 Study of Obexelimab in Patients With IgG4-Related DiseaseObexelimabPhase 3Active, not recruitingZenas BioPharma (USA), LLCDec 22, 2022

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        • Immunoglobulin G4-related sclerosing disease0.40
        • Head and neck squamous cell carcinoma0.37
        • Thyroid gland carcinoma0.37
        • Breast ductal adenocarcinoma0.37
        • Kawasaki disease0.35
        • Ulcerative proctosigmoiditis0.32

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4662940, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P31994, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.